Enfuvirtide

FDA-approved HIV fusion inhibitorEstablished

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.

For research use only.

Key Facts

FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.

Dosage Range: 90 mg twice daily
Frequency: Twice daily
Cycle: Long-term use as part of antiretroviral regimen
Administration Route: Subcutaneous
Reconstitution Guide: Reconstitute 90 mg vial with 1.1 mL sterile water for injection

36-amino-acid peptide that binds gp41 HR1, blocking six-helix-bundle formation and HIV-1 fusion with the host cell membrane.

HIV-1 gp41

Salvage HIV therapyNovel fusion-inhibitor class